RENALYTIX PLC LS-0025 risk profile
75 Stretched several inputs deteriorating together
Measured 1 September 2026 from 2O9's filed statements. Recomputed nightly.
75 (Stretched), driven by Leverage and coverage at 93, over 4 weighted categories on the SOFTWARE profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 84 | Acute | Stable | Drawdown from the 52-week high — 67.9% |
| Operating pressure | 1 | Contained | Easing | Input-cost exposure — 0.01 |
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 93 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 87 | Acute | Stable | Operating-margin gap against peers — -374.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for RENALYTIX PLC LS-0025